Loading...
Market
Efficacy Comparison of Takeda's vs Existing Dengue Vaccine by 2025
5
Resolution / Starting Odds
Higher efficacy • 33%
Equal efficacy • 34%
Lower efficacy • 33%
Comparative studies in peer-reviewed medical journals
Story
WHO Prequalifies Takeda's New Second Dengue Vaccine Amid Rising Outbreaks
May 15, 2024, 05:16 PM
The World Health Organization (WHO) has prequalified Takeda Pharmaceuticals' new dengue vaccine, marking it as the second dengue vaccine approved amid rising outbreaks in the Americas. The WHO recommends the vaccine for use in children aged 6 to 16 years in areas with high dengue burden and transmission intensity. This new vaccine aims to boost the fight against dengue fever, a vector-borne disease transmitted by mosquitoes, with over 100-400 million cases reported worldwide each year.
View original story
Similar markets
Below 50% effectiveness • 33%
50-75% effectiveness • 34%
Above 75% effectiveness • 33%
Below 20% market share • 33%
20-40% market share • 34%
Above 40% market share • 33%
Less than 20 countries • 33%
20-50 countries • 34%
More than 50 countries • 33%
Highly effective • 33%
Moderately effective • 33%
Ineffective • 34%
Below 50% effective • 33%
50% to 75% effective • 34%
Above 75% effective • 33%
Under 50% effective • 33%
50-75% effective • 33%
Over 75% effective • 33%
Below 50% effective • 25%
50%-70% effective • 25%
71%-90% effective • 25%
More than 90% effective • 25%
Below 20% effective • 25%
20-40% effective • 25%
41-60% effective • 25%
Above 60% effective • 25%
Below 50% effective • 25%
50-69% effective • 25%
70-89% effective • 25%
90% or more effective • 25%